Hypotension During Pembrolizumab Infusion: Case Report and Literature Review / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 738-740, 2019.
Article
em Zh
| WPRIM
| ID: wpr-775562
Biblioteca responsável:
WPRO
ABSTRACT
Immunological checkpoint inhibitors have been approved for a short period of time in China, and real-world clinical data are still in the collection stage. Reports of domestic programmed death-1 (PD-1) treatment-related adverse reactions are rare. The author reported a case of hypotension in the process of Pembrolizumab infusion and successful infusion after blood pressure recovery, hoping to provide reference for the application of immunological checkpoint inhibitors, to provide patients with the greatest clinical benefit.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2019
Tipo de documento:
Article